Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity.

A novel series of acenaphtho[1,2-b]pyrrole derivatives as potent and selective inhibitors of fibroblast growth factor receptor 1 (FGFR1) were designed and synthesized. In silico target prediction revealed that tyrosine kinases might be the potential targets of the representative compound 2, which was subsequently validated by enzyme-linked immunosorbent assay (ELISA) for its selective and active FGFR1 inhibition of various tyrosine kinases. The structure-activity relationship (SAR) analysis aided by molecular docking simulation in the ATP-binding site demonstrated that acenaphtho[1,2-b]pyrrole carboxylic acid esters (2-5) are potent inhibitors of FGFR1 with IC(50) values ranging from 19 to 77 nM. Furthermore, these compounds exhibited favorable growth inhibition property against FGFR-expressing cancer cell lines with IC(50) values ranging from micromolar to submicromolar. Western blotting analysis showed that compounds 2, 3, and 2b inhibited activation of FGFR1 and extracellular-signal regulated kinase 1/2 (Erk1/2).

[1]  Versatile acenaphtho[1,2-b]pyrrol-carbonitriles as a new family of heterocycles: diverse SNArH reactions, cytotoxicity and spectral behavior , 2005 .

[2]  X. Qian,et al.  Design, synthesis, and antitumor evaluation of novel acenaphtho[1,2-b]pyrrole-carboxylic acid esters with amino chain substitution. , 2006, Bioorganic & medicinal chemistry.

[3]  Zhichao Zhang,et al.  3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. , 2011, Journal of medicinal chemistry.

[4]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[5]  K. Glaser,et al.  7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. , 2008, Journal of medicinal chemistry.

[6]  E. Dreassi,et al.  Synthesis and biological evaluation of guanidino compounds endowed with subnanomolar affinity as competitive inhibitors of maize polyamine oxidase. , 2009, Journal of medicinal chemistry.

[7]  K. Bland,et al.  Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. , 2003, The Journal of surgical research.

[8]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[9]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[10]  Zoe Cournia,et al.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. , 2009, Journal of medicinal chemistry.

[11]  Meredith C Henderson,et al.  Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  V. Mersch-Sundermann,et al.  Induction of apoptosis in tumor cells by naturally occurring sulfur-containing compounds. , 2005, Mutation research.

[13]  X. Qian,et al.  A new class of long-wavelength fluorophores: strong red fluorescence, convenient synthesis and easy derivation. , 2005, Chemical communications.

[14]  M. Knowles,et al.  Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. , 2009, Cancer research.

[15]  D. Fabbro,et al.  Su-6668. SUGEN. , 2001, Current opinion in investigational drugs.

[16]  S. Hubbard,et al.  SU 6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors 1 , 2000 .

[17]  A. Coskun,et al.  An acenaphthopyrrolone-dipicolylamine derivative as a selective and sensitive chemosensor for group IIB cations , 2006 .

[18]  Zigang Dong,et al.  Cancer prevention research — then and now , 2009, Nature Reviews Cancer.

[19]  Martin Stahl,et al.  Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.

[20]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[21]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[22]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[23]  K. Parang,et al.  Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase. , 2006, Journal of medicinal chemistry.

[24]  N. Lemoine,et al.  Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer , 1994, International journal of cancer.

[25]  M. Huang,et al.  R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II , 2007, Molecular Cancer Therapeutics.

[26]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[27]  Yuan Zhao,et al.  Computation of Octanol-Water Partition Coefficients by Guiding an Additive Model with Knowledge , 2007, J. Chem. Inf. Model..

[28]  Jian Ding,et al.  GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms , 2009, Acta Pharmacologica Sinica.

[29]  D. O'Hagan,et al.  Fluorine in medicinal chemistry: A review of anti-cancer agents , 2006 .

[30]  T. Seki,et al.  Alkenyl group is responsible for the disruption of microtubule network formation in human colon cancer cell line HT-29 cells , 2008, Carcinogenesis.

[31]  X. Qian,et al.  Acenaphtho[1,2-b]pyrrole derivatives as new family of intercalators: various DNA binding geometry and interesting antitumor capacity. , 2006, Bioorganic & medicinal chemistry.

[32]  Cheng Luo,et al.  Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. , 2010, Journal of medicinal chemistry.

[33]  J. Fargnoli,et al.  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. , 2005, Journal of medicinal chemistry.

[34]  Xiaoyan Zhang,et al.  A photostable fluorescent probe for targeted imaging of tumour cells possessing integrin alpha(v)beta(3). , 2009, Molecular bioSystems.

[35]  Yufang Xu,et al.  A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. , 2010, Journal of medicinal chemistry.

[36]  X. Qian,et al.  Novel Bcl‐2 Inhibitors: Discovery and Mechanism Study of Small Organic Apoptosis‐Inducing Agents , 2007, Chembiochem : a European journal of chemical biology.

[37]  B. Delage,et al.  Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. , 2008, Carcinogenesis.

[38]  Jian Ding,et al.  Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. , 2008, Journal of medicinal chemistry.

[39]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[40]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[41]  J. Milner,et al.  Allyl sulfides from garlic suppress the in vitro proliferation of human A549 lung tumor cells. , 1997, Nutrition and cancer.

[42]  Shishir Shishodia,et al.  Molecular targets of dietary agents for prevention and therapy of cancer. , 2006, Biochemical pharmacology.

[43]  M. Botta,et al.  Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). , 2003, Current pharmaceutical design.

[44]  Tao Yi,et al.  A highly selective fluorescence turn-on sensor for cysteine/homocysteine and its application in bioimaging. , 2007, Journal of the American Chemical Society.

[45]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[46]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[47]  Yufang Xu,et al.  Sulfur-substituted naphthalimides as photoactivatable anticancer agents: DNA interaction, fluorescence imaging, and phototoxic effects in cultured tumor cells. , 2008, Bioorganic & medicinal chemistry.

[48]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[49]  William L Jorgensen,et al.  Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. , 2010, Journal of medicinal chemistry.

[50]  V. Stoll,et al.  Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. , 2009, Journal of medicinal chemistry.

[51]  Qiang He,et al.  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. , 2010, ACS medicinal chemistry letters.

[52]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[53]  Pascal Furet,et al.  Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.

[54]  Hualiang Jiang,et al.  Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme. , 2007, Bioorganic & medicinal chemistry.

[55]  S. Cook,et al.  De-regulated FGF receptors as therapeutic targets in cancer. , 2010, Pharmacology & therapeutics.

[56]  A. Kraft,et al.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. , 2009, Journal of medicinal chemistry.

[57]  Scott B Ficarro,et al.  A structure-guided approach to creating covalent FGFR inhibitors. , 2010, Chemistry & biology.